Boost for Genomic Health as Oncotype DX makes ASCO (American Society of Clinical Oncology's) guidelines:
This article was originally published in Clinica
Genomic Health's breast cancer prognostic - Oncotype Dx - has been included in the American Society of Clinical Oncology's (ASCO) updated guidelines. The move could spell a boost in sales for the product, which is used to determine the likelihood of disease recurrence and of chemotherapy benefit for node-negative, oestrogen receptor-positive patients. The guidelines will appear in the Journal of Clinical Oncology on November 20. The inclusion of Oncotype DX is based on multiple independent clinical studies involving over 2,600 patients, claimed the Redwood City, California firm. ASCO guidelines serve as a guide for doctors and outline appropriate methods for treatment and care.